Advaxis to Present at Jefferies 2017 Global Healthcare Conference
June 07 2017 - 8:30AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company
developing cancer immunotherapies, today announced that Daniel J.
O’Connor, President and Chief Executive Officer of Advaxis, will
present a company overview at the Jefferies 2017 Global Healthcare
Conference being held June 6-9, 2017 in New York, NY.
Event: Jefferies 2017 Global Healthcare
ConferencePresentation Date: June 7, 2017Presentation
Time: 10:30 a.m. ETLocation: Grand Hyatt, New York,
NY
Presentation slides will be available following the event at
ir.advaxis.com.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a late-stage
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology™. Lm Technology,
using bioengineered live attenuated Listeria
monocytogenes (Lm) bacteria, is the only known cancer
immunotherapy agent shown in preclinical studies to both generate
cancer fighting T cells directed against cancer antigens and
neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that
protect the tumor microenvironment from immunologic attack and
contribute to tumor growth. Advaxis' lead Lm Technology
immunotherapy, axalimogene filolisbac, targets HPV-associated
cancers and is currently has multiple clinical trials underway,
including Phase 3 in invasive cervical cancer, Phase 2 in head and
neck cancer, and Phase 2 in anal cancer. The FDA has granted
axalimogene filolisbac orphan drug designation for each of these
three clinical settings, as well as Fast Track designation for
adjuvant therapy for high-risk, locally advanced cervical cancer
(HRLACC) patients and a Special Protocol Assessment agreement for
the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene
filolisbac has also been classified as an advanced therapy
medicinal product for the treatment of cervical cancer by the
European Medicines Agency’s Committee for Advanced Therapies.
Advaxis has two additional immunotherapy products: ADXS-PSA in
prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in
human clinical development. In addition, Advaxis and Amgen are
developing ADXS-NEO, an investigational cancer immunotherapy
treatment designed to activate a patient's immune system to respond
against the unique mutations, or neoepitopes, contained in and
identified from each individual patient's tumor, with plans to
enter the clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop the next generation of cancer immunotherapies,
and the safety and efficacy of Advaxis’ proprietary immunotherapy,
axalimogene filolisbac. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170607005726/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
Affairsheber@advaxis.comorMedia Contact:JPA Health
CommunicationsDavid Connolly, 617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024